Jylamvo in Egypt
How patients in Egypt access Jylamvo (methotrexate oral solution) via Named Patient Program.
Jylamvo - overview
Jylamvo (methotrexate oral solution) is manufactured by Medac / STADA and indicated for acute lymphoblastic leukemia, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis, and severe psoriasis (age- and indication-specific). It is an oral solution, ready-to-use methotrexate 2 mg/mL approved by the US FDA in 2022 and may be accessible to patients in Egypt through a Named Patient Program or personal-import pathway.
Access in Egypt
Egypt's EDA permits personal-use import of non-registered drugs under physician supervision; process is paperwork-heavy but viable.
How Reserve Meds coordinates access in Egypt
- Patient or treating physician submits a request.
- We verify clinical appropriateness and Egypt-specific eligibility.
- Treating physician in Egypt issues prescription and clinical justification.
- Country-specific NPP/personal-import forms are prepared and filed.
- We source Jylamvo from a DSCSA-compliant US specialty wholesaler.
- Cold-chain shipment to the patient's physician or hospital pharmacy in Egypt.
Typical timeline for Egypt
End-to-end, most requests are completed in 2-6 weeks. Egypt's tier 2 regulatory maturity typically supports moderate processing times.
What patients and physicians in Egypt ask
- Is the pathway legal in Egypt? Yes - it operates under Egypt's established NPP or personal-import framework.
- Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
- What physician credentials do I need? A licensed physician in Egypt able to issue the prescription and clinical justification.
- What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
- Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.